社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Psyence Biomedical Ltd(PBM)
盘前
0.9000
-0.03
-3.23%
08:01 EST
0.9300
+0.0220
+2.42%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
鹰瞳科技_Airdoc
·
11-17
2025全国斜视与小儿眼科学术大会丨鹰瞳PBM视力康复仪发布「近视前期」临床研究
2025年11月6日-8日,由安徽省医学会主办,安徽医科大学第一附属医院与天津市眼科医院(南开大学附属天津市眼科医院)承办的“2025年全国斜视与小儿眼科学术大会”在合肥举办。期间,鹰瞳科技(Airdoc)于11月8日发布针对近视前期儿童使用鹰瞳PBM®视力康复仪的临床研究新进展,旨在贯彻关于儿童青少年近视防控工作的重要指示批示精神,为推动近视防控关口前移,探索基于AI与PBM®无创光疗技术保护儿童远视储备量的前沿方案。 AI与PBM®技术 科学守护儿童远视储备 2025年10月31日,教育部联合国家卫生健康委、国家疾控局印发《关于科学保护儿童远视储备量的通知》,推动近视防控关口前移,多措并举保护儿童远视储备量。 《通知》在国家层面首次明确将“远视储备量”作为近视防控的重点关注事项,远视储备量是儿童视觉发育过程中的“生理储备”,其过早消耗是近视发生的早期信号。 推动近视防控关口前移、保护儿童远视储备量,对青少年近视防控工作至关重要。AI与PBM®无创光疗技术对处于近视前期的孩子有什么价值?又是如何保护远视储备量、有效预防近视的呢? 首先,AI技术可整合多维度数据,构建近视风险预测模型,实现早期预警与个性化干预。如鹰瞳万语大模型能够基于未近视儿童的数据,运用生成式人工智能技术进行精准预测,判断其何时可能发展为近视。对于已经近视的儿童,万语大模型则能准确预测其近视度数的月度进展、眼轴变化以及屈光状态的发展趋势。这种预测能力为家长和医生提供了宝贵的早期预警,使他们能够及时采取干预措施,有效延缓近视的发展。 其次,PBM®无创光疗技术在近视前期儿童的应用,临床有效性已得到验证。在2025年全国斜视与小儿眼科学术大会期间,华中科技大学同济医学院附属协和医院的石冰洁医生报告的《PBM-LED®在近视前期儿童的临床应用》研究数据显示,近视前期儿童使用鹰瞳PBM®视力康复仪(即PBM-LE
2025全国斜视与小儿眼科学术大会丨鹰瞳PBM视力康复仪发布「近视前期」临床研究
回复
评论
点赞
1
编组 21备份 2
分享
举报
鹰瞳科技_Airdoc
·
11-07
CCTV《预见视界》报道鹰瞳PBM近视防控
10月9日世界视力日,CCTV央视网《预见视界》栏目深入近视防控领域,邀请眼科医学权威专家展开深度对话,并报道了鹰瞳科技自主研发的PBM®近视防控产品。 鹰瞳PBM®视力康复仪基于光生物调节技术,产品设计原则为安全至上,采用环形光斑照射,避开视网膜黄斑中心凹区域,能够更安全有效地守护儿童清晰视觉,预见更好未来。 2025年7月,国家药监局发布《含光源的近视控制、弱视治疗类医疗器械产品分类界定指导原则的通告(2025年第25号)》。这一政策不仅明确了 “安全至上” 的防控原则,也让家长在选择近视防控产品时,有了更清晰的安全指引。 PBM®视力康复仪经国家药监局批准用于预防近视和辅助治疗近视,并获得国家知识产权局发明专利和第48届日内瓦国际发明展特别嘉许金奖。2025服贸会上,众多嘉宾亲测PBM®视力康复仪,现场给予广泛好评。同期,PBM®视力康复仪在学界也展现优势。 在2025 CCOS中华医学会第二十九次眼科学术大会、江苏省妇幼保健协会儿童眼病防治专业委员会2025年学术年会上,众多眼科专家与AI企业齐聚,探索PBM®无创光疗方案的安全性与有效性,深入剖析光生物调节技术原理、应用前景,为行业、学术界指明新方向、提供新参考。 权威认证+临床验证 PBM®无创光疗技术实力有保障 鹰瞳PBM®视力康复仪经过严谨的临床验证安全有效。在2025 CCOS 中华医学会眼科学术大会上,上海交通大学医学院附属上海儿童医学中心眼科刘红教授(在接受央视网《预见视界》采访时)提到,传统近视防控手段有效率虽超 60%,但仍有部分孩子“没效果”。学者们已开始探索基于光生物调节技术PBM®无创光疗的应用和组合应用方案,提升防控有效性。 刘红教授还提到,采用特殊设计的LED光(鹰瞳PBM®视力康复仪)对眼底更安全。该中心相关临床实验的结果也进一步表明了鹰瞳PBM®视力康复仪的有效性,为近视防控开辟了新思
CCTV《预见视界》报道鹰瞳PBM近视防控
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
鹰瞳科技_Airdoc
·
11-03
Bright China 2025丨鹰瞳PBM视力康复仪临床研究数据发布
10月24日-26日,Bright China 2025明眸中国近视防控大会暨国际近视研讨会在上海举办。会议期间,鹰瞳科技(Airdoc)于10月26日联合多位权威专家举办了以「PBM®光生物调节临床研究和展望」为主题的卫星会,发布应用鹰瞳PBM®视力康复仪的临床研究数据,旨在推动近视防控事业高质量发展,助力实现国家近视防控健康战略目标。 在「灯塔·标准与指南」专题研讨会上,上海眼病防治中心的邹海东教授介绍了鹰瞳PBM®视力康复仪的临床试验进展。邹教授提到:“目前正在开展的临床试验数据显示,应用鹰瞳PBM®视力康复仪对比安慰剂可有效控制眼轴长度和屈光度的近视化漂移。” 与此同时,「PBM®光生物调节临床研究和展望」专题卫星会由上海交通大学医学院附属第一人民医院王小娟教授与上海交通大学医学院附属新华医院于军教授共同主持。会上,上海眼病防治中心何鲜桂教授、上海儿童医学中心刘红教授及南京医科大学附属儿童医院陈志钧教授作了精彩专题报告,深度剖析了PBM光生物调节技术在近视防控领域的突破性进展。 Bright China 2025丨鹰瞳卫星会主持人王小娟(左)教授、于军(右)教授 单用鹰瞳PBM®视力康复仪 临床研究数据 上海市眼病防治中心何鲜桂教授指出,尽管目前临床已有多种近视防控手段,但儿童青少年个体差异显著,部分孩子对常规干预措施应答不佳,亟需探索更精准、个性化的补充方案。在此背景下,PBM光生物调节技术凭借其非侵入性、安全性高、协同性强等优势,成为当前研究热点与临床实践的重要选择。 上海市眼病防治中心开展了一项单中心、随机对照的“LED红光控制近视进展”预实验,研究纳入40名8-12岁单纯性近视儿童,分为干预组和对照组,每组各20人。干预组接受鹰瞳PBM®视力康复仪照射(2次/日,3分钟/次),对照组采用极低剂量照射(0.001mW,模拟安慰剂)。 预实验研究数据显示,干预组
Bright China 2025丨鹰瞳PBM视力康复仪临床研究数据发布
回复
评论
点赞
1
编组 21备份 2
分享
举报
鹰瞳科技_Airdoc
·
09-14
鹰瞳Airdoc参建国家人工智能应用中试基地,PBM广受青睐
图:国务院副总理丁薛祥和北京市委书记尹力巡视服贸会,在鹰瞳Airdoc AI健康产品展台驻足。 北京卫视《北京新闻》报道: 2025年中国国际服务贸易交易会于9月10号在北京举行。中共中央政治局常委、国务院副总理丁薛祥出席全球服务贸易峰会并发表主旨讲话。峰会结束后,丁薛祥和尹力一起巡视服贸会展馆,在与参展单位负责人交流时,丁薛祥说:“中国将持续推进高水平对外开放,积极扩大优质服务进出口,为中外企业提供更多发展机遇,更好满足各国人民美好生活需要。” 丁薛祥副总理和北京市委书记尹力在健康卫生服务展区,听取了国家人工智能应用中试基地(医疗领域)的汇报。鹰瞳Airdoc作为国家人工智能应用中试基地(医疗领域)的合作生态之一,在本届服贸会展示了多款AI健康创新产品。 服贸会参会人员体验了鹰瞳Airdoc PBM视力康复仪、鹰瞳Airdoc视网膜慢病风险评估、鹰瞳Airdoc人工智能抗压能力监测等人工智能健康产品。鹰瞳Airdoc AI健康产品吸引了新华社、CCTV-2财经、央视新闻客户端、央广网、央视频等多家媒体记者的关注,并获得广泛关注与报道。 鹰瞳科技(Airdoc)AI健康产品在服贸会大放异彩,备受关注。在2号馆公益展区优促计划主题展上,鹰瞳Airdoc邀请参会嘉宾亲测PBM视力康复仪等创新产品,赢得参会嘉宾的广泛青睐,而同期PBM视力康复仪在学界也展现优势。 PBM 技术与脑机接口关联及在近视问题上的探索:「政策推动与技术融合」 近年来,随着科学技术的迅猛发展,脑机接口(Brain-Computer Interface, BCI)技术已成为前沿科技创新的重要方向。与此同时,光生物调节(PBM)作为一种新兴技术路径,也逐渐崭露头角,并与脑机接口技术形成多层面的交叉与融合。 脑机接口通过在脑与机器之间建立信息通道,实现生物智能与机器智能的协同交互,是生命科学和信息科学融合发展的前
鹰瞳Airdoc参建国家人工智能应用中试基地,PBM广受青睐
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
我就是阿硕
·
2024-07-25
$Psyence Biomedical Ltd(PBM)$
$Psyence Biomedical Ltd(PBM)$
# 晒晒更赚钱
回复
评论
点赞
1
编组 21备份 2
分享
举报
小谷AI洞察
·
2024-06-21
$Psyence Biomedical Ltd(PBM)$
套人的东西,早上进来了,现在迭得只剩下1/3了
$Psyence Biomedical Ltd(PBM)$ 套人的东西,早上进来了,现在迭得只剩下1/3了
精彩
愫暮_9408:
你是因为啥原因买这个股啊[捂脸]
回复
2
点赞
点赞
编组 21备份 2
分享
举报
小谷AI洞察
·
2024-06-21
$Psyence Biomedical Ltd(PBM)$
1块进的,腰斩了
$Psyence Biomedical Ltd(PBM)$ 1块进的,腰斩了
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
小谷AI洞察
·
2024-06-21
$Psyence Biomedical Ltd(PBM)$
?
$Psyence Biomedical Ltd(PBM)$ ?
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
愫暮_9408
·
2024-04-17
$Psyence Biomedical Ltd(PBM)$
怎么能一直跌[捂脸] [捂脸]
$Psyence Biomedical Ltd(PBM)$ 怎么能一直跌[捂脸] [捂脸]
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
Psyence Biomedical Ltd
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.pacificbooker.bc.ca
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Psyence Biomedical Ltd是一家生命科学生物技术公司,率先在心理健康和福祉中使用天然迷幻药物。它开发天然的迷幻药产品,用于在姑息治疗背景下治愈心理创伤及其心理健康后果。该公司已开始临床试验程序,以评估其候选产品的安全性和有效性。它在其位于南部非洲的联邦许可的 ISO22000 设施中种植天然迷幻药蘑菇。该产品是为出口到世界各地的合作伙伴而生产的,然后加工成标准化的封装产品。
10-14
[修订]招股说明书
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
10-06
[修订]招股说明书
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
07-25
[修订]年度报告
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
07-23
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
06-25
年度报告
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
03-13
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
01-28
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
01-24
招股说明书
Form F-1 - Registration statement for certain foreign private issuers
Form F-1 - Registration statement for certain foreign private issuers
2024-12-30
SEC问询函
Form CORRESP - Correspondence
Form CORRESP - Correspondence
2024-12-20
招股说明书
Form F-1 - Registration statement for certain foreign private issuers
Form F-1 - Registration statement for certain foreign private issuers
2024-12-13
超过5%披露
Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024-12-09
超过5%披露
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024-12-04
超过5%披露
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024-11-13
超过5%披露
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024-11-12
超过5%披露
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
分时
5日
日
周
月
数据加载中...
最高
0.9500
今开
0.8470
量比
0.12
最低
0.8000
昨收
0.9080
换手率
46.52%
热议股票
{"pagemeta":{"title":"Psyence Biomedical Ltd(PBM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Psyence Biomedical Ltd(PBM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Psyence Biomedical Ltd(PBM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"PBM","data":{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":0.93,"timestamp":1766523600000,"preClose":0.908,"halted":0,"volume":865196,"hourTrading":{"tag":"盘前","latestPrice":0.9,"preClose":0.93,"latestTime":"08:01 EST","volume":1611,"amount":1425.4994718,"timestamp":1766581285352},"delay":0,"floatShares":1859800,"shares":1867200,"eps":-5.565065,"marketStatus":"盘前交易","change":0.022,"latestTime":"12-24 08:02:32 EST","open":0.847,"high":0.95,"low":0.8,"amount":764195.2944254801,"amplitude":0.165198,"askPrice":0.93,"askSize":68,"bidPrice":0.88,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-5.565065,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766586600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.93,"preHourTrading":{"tag":"盘前","latestPrice":0.9,"preClose":0.93,"latestTime":"08:01 EST","volume":1611,"amount":1425.4994718,"timestamp":1766581285352},"postHourTrading":{"tag":"盘后","latestPrice":0.8705,"preClose":0.93,"latestTime":"19:59 EST","volume":22347,"amount":19725.5667,"timestamp":1766537958696},"volumeRatio":0.1184368119329629},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.501019879571520","cardData":[{"tweetId":"501019879571520","author":{"authorId":"4096767797929640","idStr":"4096767797929640","name":"鹰瞳科技_Airdoc","avatar":"https://static.tigerbbs.com/66b36e302f8cbc5502d09f07a802d81c","userType":5,"introduction":"鹰瞳科技(Airdoc)官方账号。我们是全球视网膜影像人工智能领域的领导者和先行者。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1063,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"2025全国斜视与小儿眼科学术大会丨鹰瞳PBM视力康复仪发布「近视前期」临床研究","digest":"2025年11月6日-8日,由安徽省医学会主办,安徽医科大学第一附属医院与天津市眼科医院(南开大学附属天津市眼科医院)承办的“2025年全国斜视与小儿眼科学术大会”在合肥举办。期间,鹰瞳科技(Airdoc)于11月8日发布针对近视前期儿童使用鹰瞳PBM®视力康复仪的临床研究新进展,旨在贯彻关于儿童青少年近视防控工作的重要指示批示精神,为推动近视防控关口前移,探索基于AI与PBM®无创光疗技术保护儿童远视储备量的前沿方案。 AI与PBM®技术 科学守护儿童远视储备 2025年10月31日,教育部联合国家卫生健康委、国家疾控局印发《关于科学保护儿童远视储备量的通知》,推动近视防控关口前移,多措并举保护儿童远视储备量。 《通知》在国家层面首次明确将“远视储备量”作为近视防控的重点关注事项,远视储备量是儿童视觉发育过程中的“生理储备”,其过早消耗是近视发生的早期信号。 推动近视防控关口前移、保护儿童远视储备量,对青少年近视防控工作至关重要。AI与PBM®无创光疗技术对处于近视前期的孩子有什么价值?又是如何保护远视储备量、有效预防近视的呢? 首先,AI技术可整合多维度数据,构建近视风险预测模型,实现早期预警与个性化干预。如鹰瞳万语大模型能够基于未近视儿童的数据,运用生成式人工智能技术进行精准预测,判断其何时可能发展为近视。对于已经近视的儿童,万语大模型则能准确预测其近视度数的月度进展、眼轴变化以及屈光状态的发展趋势。这种预测能力为家长和医生提供了宝贵的早期预警,使他们能够及时采取干预措施,有效延缓近视的发展。 其次,PBM®无创光疗技术在近视前期儿童的应用,临床有效性已得到验证。在2025年全国斜视与小儿眼科学术大会期间,华中科技大学同济医学院附属协和医院的石冰洁医生报告的《PBM-LED®在近视前期儿童的临床应用》研究数据显示,近视前期儿童使用鹰瞳PBM®视力康复仪(即PBM-LE","plainDigest":"2025年11月6日-8日,由安徽省医学会主办,安徽医科大学第一附属医院与天津市眼科医院(南开大学附属天津市眼科医院)承办的“2025年全国斜视与小儿眼科学术大会”在合肥举办。期间,鹰瞳科技(Airdoc)于11月8日发布针对近视前期儿童使用鹰瞳PBM®视力康复仪的临床研究新进展,旨在贯彻关于儿童青少年近视防控工作的重要指示批示精神,为推动近视防控关口前移,探索基于AI与PBM®无创光疗技术保护儿童远视储备量的前沿方案。 AI与PBM®技术 科学守护儿童远视储备 2025年10月31日,教育部联合国家卫生健康委、国家疾控局印发《关于科学保护儿童远视储备量的通知》,推动近视防控关口前移,多措并举保护儿童远视储备量。 《通知》在国家层面首次明确将“远视储备量”作为近视防控的重点关注事项,远视储备量是儿童视觉发育过程中的“生理储备”,其过早消耗是近视发生的早期信号。 推动近视防控关口前移、保护儿童远视储备量,对青少年近视防控工作至关重要。AI与PBM®无创光疗技术对处于近视前期的孩子有什么价值?又是如何保护远视储备量、有效预防近视的呢? 首先,AI技术可整合多维度数据,构建近视风险预测模型,实现早期预警与个性化干预。如鹰瞳万语大模型能够基于未近视儿童的数据,运用生成式人工智能技术进行精准预测,判断其何时可能发展为近视。对于已经近视的儿童,万语大模型则能准确预测其近视度数的月度进展、眼轴变化以及屈光状态的发展趋势。这种预测能力为家长和医生提供了宝贵的早期预警,使他们能够及时采取干预措施,有效延缓近视的发展。 其次,PBM®无创光疗技术在近视前期儿童的应用,临床有效性已得到验证。在2025年全国斜视与小儿眼科学术大会期间,华中科技大学同济医学院附属协和医院的石冰洁医生报告的《PBM-LED®在近视前期儿童的临床应用》研究数据显示,近视前期儿童使用鹰瞳PBM®视力康复仪(即PBM-LE","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1763360140229,"gmtModify":1763361710302,"symbols":["02251","PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":7,"images":[{"url":"https://static.tigerbbs.com/a19d16b96c9c7f34bc8275813f28a8ac","width":"1080","height":"601"},{"url":"https://static.tigerbbs.com/7cf7a8882140f02d4a92e0da872d840d","width":"1080","height":"608"},{"url":"https://static.tigerbbs.com/6d31f8bdaeb6dbf16b76e091c9479293","width":"1080","height":"720"}],"repostCount":0,"viewCount":27661,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/501019879571520","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3970,"displayRows":2,"foldSize":0,"authorId":"4096767797929640"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.497552870601456","cardData":[{"tweetId":"497552870601456","author":{"authorId":"4096767797929640","idStr":"4096767797929640","name":"鹰瞳科技_Airdoc","avatar":"https://static.tigerbbs.com/66b36e302f8cbc5502d09f07a802d81c","userType":5,"introduction":"鹰瞳科技(Airdoc)官方账号。我们是全球视网膜影像人工智能领域的领导者和先行者。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1063,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"CCTV《预见视界》报道鹰瞳PBM近视防控","digest":"10月9日世界视力日,CCTV央视网《预见视界》栏目深入近视防控领域,邀请眼科医学权威专家展开深度对话,并报道了鹰瞳科技自主研发的PBM®近视防控产品。 鹰瞳PBM®视力康复仪基于光生物调节技术,产品设计原则为安全至上,采用环形光斑照射,避开视网膜黄斑中心凹区域,能够更安全有效地守护儿童清晰视觉,预见更好未来。 2025年7月,国家药监局发布《含光源的近视控制、弱视治疗类医疗器械产品分类界定指导原则的通告(2025年第25号)》。这一政策不仅明确了 “安全至上” 的防控原则,也让家长在选择近视防控产品时,有了更清晰的安全指引。 PBM®视力康复仪经国家药监局批准用于预防近视和辅助治疗近视,并获得国家知识产权局发明专利和第48届日内瓦国际发明展特别嘉许金奖。2025服贸会上,众多嘉宾亲测PBM®视力康复仪,现场给予广泛好评。同期,PBM®视力康复仪在学界也展现优势。 在2025 CCOS中华医学会第二十九次眼科学术大会、江苏省妇幼保健协会儿童眼病防治专业委员会2025年学术年会上,众多眼科专家与AI企业齐聚,探索PBM®无创光疗方案的安全性与有效性,深入剖析光生物调节技术原理、应用前景,为行业、学术界指明新方向、提供新参考。 权威认证+临床验证 PBM®无创光疗技术实力有保障 鹰瞳PBM®视力康复仪经过严谨的临床验证安全有效。在2025 CCOS 中华医学会眼科学术大会上,上海交通大学医学院附属上海儿童医学中心眼科刘红教授(在接受央视网《预见视界》采访时)提到,传统近视防控手段有效率虽超 60%,但仍有部分孩子“没效果”。学者们已开始探索基于光生物调节技术PBM®无创光疗的应用和组合应用方案,提升防控有效性。 刘红教授还提到,采用特殊设计的LED光(鹰瞳PBM®视力康复仪)对眼底更安全。该中心相关临床实验的结果也进一步表明了鹰瞳PBM®视力康复仪的有效性,为近视防控开辟了新思","plainDigest":"10月9日世界视力日,CCTV央视网《预见视界》栏目深入近视防控领域,邀请眼科医学权威专家展开深度对话,并报道了鹰瞳科技自主研发的PBM®近视防控产品。 鹰瞳PBM®视力康复仪基于光生物调节技术,产品设计原则为安全至上,采用环形光斑照射,避开视网膜黄斑中心凹区域,能够更安全有效地守护儿童清晰视觉,预见更好未来。 2025年7月,国家药监局发布《含光源的近视控制、弱视治疗类医疗器械产品分类界定指导原则的通告(2025年第25号)》。这一政策不仅明确了 “安全至上” 的防控原则,也让家长在选择近视防控产品时,有了更清晰的安全指引。 PBM®视力康复仪经国家药监局批准用于预防近视和辅助治疗近视,并获得国家知识产权局发明专利和第48届日内瓦国际发明展特别嘉许金奖。2025服贸会上,众多嘉宾亲测PBM®视力康复仪,现场给予广泛好评。同期,PBM®视力康复仪在学界也展现优势。 在2025 CCOS中华医学会第二十九次眼科学术大会、江苏省妇幼保健协会儿童眼病防治专业委员会2025年学术年会上,众多眼科专家与AI企业齐聚,探索PBM®无创光疗方案的安全性与有效性,深入剖析光生物调节技术原理、应用前景,为行业、学术界指明新方向、提供新参考。 权威认证+临床验证 PBM®无创光疗技术实力有保障 鹰瞳PBM®视力康复仪经过严谨的临床验证安全有效。在2025 CCOS 中华医学会眼科学术大会上,上海交通大学医学院附属上海儿童医学中心眼科刘红教授(在接受央视网《预见视界》采访时)提到,传统近视防控手段有效率虽超 60%,但仍有部分孩子“没效果”。学者们已开始探索基于光生物调节技术PBM®无创光疗的应用和组合应用方案,提升防控有效性。 刘红教授还提到,采用特殊设计的LED光(鹰瞳PBM®视力康复仪)对眼底更安全。该中心相关临床实验的结果也进一步表明了鹰瞳PBM®视力康复仪的有效性,为近视防控开辟了新思","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1762495546946,"gmtModify":1762496630120,"symbols":["02251","PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":6,"images":[{"url":"https://static.tigerbbs.com/3d1746d7372bbf3926345e8a69cb8844","width":"720","height":"405"},{"url":"https://static.tigerbbs.com/596ae00e36513f334d2b8913b22456e6","width":"720","height":"405"},{"url":"https://static.tigerbbs.com/65ea057a8b5c2f07179c9e3023a9a30b","width":"720","height":"405"}],"repostCount":0,"viewCount":27302,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/497552870601456","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3515,"displayRows":2,"foldSize":0,"authorId":"4096767797929640"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.496046938783768","cardData":[{"tweetId":"496046938783768","author":{"authorId":"4096767797929640","idStr":"4096767797929640","name":"鹰瞳科技_Airdoc","avatar":"https://static.tigerbbs.com/66b36e302f8cbc5502d09f07a802d81c","userType":5,"introduction":"鹰瞳科技(Airdoc)官方账号。我们是全球视网膜影像人工智能领域的领导者和先行者。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1063,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"Bright China 2025丨鹰瞳PBM视力康复仪临床研究数据发布","digest":"10月24日-26日,Bright China 2025明眸中国近视防控大会暨国际近视研讨会在上海举办。会议期间,鹰瞳科技(Airdoc)于10月26日联合多位权威专家举办了以「PBM®光生物调节临床研究和展望」为主题的卫星会,发布应用鹰瞳PBM®视力康复仪的临床研究数据,旨在推动近视防控事业高质量发展,助力实现国家近视防控健康战略目标。 在「灯塔·标准与指南」专题研讨会上,上海眼病防治中心的邹海东教授介绍了鹰瞳PBM®视力康复仪的临床试验进展。邹教授提到:“目前正在开展的临床试验数据显示,应用鹰瞳PBM®视力康复仪对比安慰剂可有效控制眼轴长度和屈光度的近视化漂移。” 与此同时,「PBM®光生物调节临床研究和展望」专题卫星会由上海交通大学医学院附属第一人民医院王小娟教授与上海交通大学医学院附属新华医院于军教授共同主持。会上,上海眼病防治中心何鲜桂教授、上海儿童医学中心刘红教授及南京医科大学附属儿童医院陈志钧教授作了精彩专题报告,深度剖析了PBM光生物调节技术在近视防控领域的突破性进展。 Bright China 2025丨鹰瞳卫星会主持人王小娟(左)教授、于军(右)教授 单用鹰瞳PBM®视力康复仪 临床研究数据 上海市眼病防治中心何鲜桂教授指出,尽管目前临床已有多种近视防控手段,但儿童青少年个体差异显著,部分孩子对常规干预措施应答不佳,亟需探索更精准、个性化的补充方案。在此背景下,PBM光生物调节技术凭借其非侵入性、安全性高、协同性强等优势,成为当前研究热点与临床实践的重要选择。 上海市眼病防治中心开展了一项单中心、随机对照的“LED红光控制近视进展”预实验,研究纳入40名8-12岁单纯性近视儿童,分为干预组和对照组,每组各20人。干预组接受鹰瞳PBM®视力康复仪照射(2次/日,3分钟/次),对照组采用极低剂量照射(0.001mW,模拟安慰剂)。 预实验研究数据显示,干预组","plainDigest":"10月24日-26日,Bright China 2025明眸中国近视防控大会暨国际近视研讨会在上海举办。会议期间,鹰瞳科技(Airdoc)于10月26日联合多位权威专家举办了以「PBM®光生物调节临床研究和展望」为主题的卫星会,发布应用鹰瞳PBM®视力康复仪的临床研究数据,旨在推动近视防控事业高质量发展,助力实现国家近视防控健康战略目标。 在「灯塔·标准与指南」专题研讨会上,上海眼病防治中心的邹海东教授介绍了鹰瞳PBM®视力康复仪的临床试验进展。邹教授提到:“目前正在开展的临床试验数据显示,应用鹰瞳PBM®视力康复仪对比安慰剂可有效控制眼轴长度和屈光度的近视化漂移。” 与此同时,「PBM®光生物调节临床研究和展望」专题卫星会由上海交通大学医学院附属第一人民医院王小娟教授与上海交通大学医学院附属新华医院于军教授共同主持。会上,上海眼病防治中心何鲜桂教授、上海儿童医学中心刘红教授及南京医科大学附属儿童医院陈志钧教授作了精彩专题报告,深度剖析了PBM光生物调节技术在近视防控领域的突破性进展。 Bright China 2025丨鹰瞳卫星会主持人王小娟(左)教授、于军(右)教授 单用鹰瞳PBM®视力康复仪 临床研究数据 上海市眼病防治中心何鲜桂教授指出,尽管目前临床已有多种近视防控手段,但儿童青少年个体差异显著,部分孩子对常规干预措施应答不佳,亟需探索更精准、个性化的补充方案。在此背景下,PBM光生物调节技术凭借其非侵入性、安全性高、协同性强等优势,成为当前研究热点与临床实践的重要选择。 上海市眼病防治中心开展了一项单中心、随机对照的“LED红光控制近视进展”预实验,研究纳入40名8-12岁单纯性近视儿童,分为干预组和对照组,每组各20人。干预组接受鹰瞳PBM®视力康复仪照射(2次/日,3分钟/次),对照组采用极低剂量照射(0.001mW,模拟安慰剂)。 预实验研究数据显示,干预组","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1762136196995,"gmtModify":1762136763408,"symbols":["02251","PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":9,"images":[{"url":"https://static.tigerbbs.com/1e22f25e86c5c81ebcb5c256e664184f","width":"693","height":"462"}],"repostCount":0,"viewCount":28770,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/496046938783768","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3296,"displayRows":2,"foldSize":0,"authorId":"4096767797929640"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.478447991959848","cardData":[{"tweetId":"478447991959848","author":{"authorId":"4096767797929640","idStr":"4096767797929640","name":"鹰瞳科技_Airdoc","avatar":"https://static.tigerbbs.com/66b36e302f8cbc5502d09f07a802d81c","userType":5,"introduction":"鹰瞳科技(Airdoc)官方账号。我们是全球视网膜影像人工智能领域的领导者和先行者。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1063,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"鹰瞳Airdoc参建国家人工智能应用中试基地,PBM广受青睐","digest":"图:国务院副总理丁薛祥和北京市委书记尹力巡视服贸会,在鹰瞳Airdoc AI健康产品展台驻足。 北京卫视《北京新闻》报道: 2025年中国国际服务贸易交易会于9月10号在北京举行。中共中央政治局常委、国务院副总理丁薛祥出席全球服务贸易峰会并发表主旨讲话。峰会结束后,丁薛祥和尹力一起巡视服贸会展馆,在与参展单位负责人交流时,丁薛祥说:“中国将持续推进高水平对外开放,积极扩大优质服务进出口,为中外企业提供更多发展机遇,更好满足各国人民美好生活需要。” 丁薛祥副总理和北京市委书记尹力在健康卫生服务展区,听取了国家人工智能应用中试基地(医疗领域)的汇报。鹰瞳Airdoc作为国家人工智能应用中试基地(医疗领域)的合作生态之一,在本届服贸会展示了多款AI健康创新产品。 服贸会参会人员体验了鹰瞳Airdoc PBM视力康复仪、鹰瞳Airdoc视网膜慢病风险评估、鹰瞳Airdoc人工智能抗压能力监测等人工智能健康产品。鹰瞳Airdoc AI健康产品吸引了新华社、CCTV-2财经、央视新闻客户端、央广网、央视频等多家媒体记者的关注,并获得广泛关注与报道。 鹰瞳科技(Airdoc)AI健康产品在服贸会大放异彩,备受关注。在2号馆公益展区优促计划主题展上,鹰瞳Airdoc邀请参会嘉宾亲测PBM视力康复仪等创新产品,赢得参会嘉宾的广泛青睐,而同期PBM视力康复仪在学界也展现优势。 PBM 技术与脑机接口关联及在近视问题上的探索:「政策推动与技术融合」 近年来,随着科学技术的迅猛发展,脑机接口(Brain-Computer Interface, BCI)技术已成为前沿科技创新的重要方向。与此同时,光生物调节(PBM)作为一种新兴技术路径,也逐渐崭露头角,并与脑机接口技术形成多层面的交叉与融合。 脑机接口通过在脑与机器之间建立信息通道,实现生物智能与机器智能的协同交互,是生命科学和信息科学融合发展的前","plainDigest":"图:国务院副总理丁薛祥和北京市委书记尹力巡视服贸会,在鹰瞳Airdoc AI健康产品展台驻足。 北京卫视《北京新闻》报道: 2025年中国国际服务贸易交易会于9月10号在北京举行。中共中央政治局常委、国务院副总理丁薛祥出席全球服务贸易峰会并发表主旨讲话。峰会结束后,丁薛祥和尹力一起巡视服贸会展馆,在与参展单位负责人交流时,丁薛祥说:“中国将持续推进高水平对外开放,积极扩大优质服务进出口,为中外企业提供更多发展机遇,更好满足各国人民美好生活需要。” 丁薛祥副总理和北京市委书记尹力在健康卫生服务展区,听取了国家人工智能应用中试基地(医疗领域)的汇报。鹰瞳Airdoc作为国家人工智能应用中试基地(医疗领域)的合作生态之一,在本届服贸会展示了多款AI健康创新产品。 服贸会参会人员体验了鹰瞳Airdoc PBM视力康复仪、鹰瞳Airdoc视网膜慢病风险评估、鹰瞳Airdoc人工智能抗压能力监测等人工智能健康产品。鹰瞳Airdoc AI健康产品吸引了新华社、CCTV-2财经、央视新闻客户端、央广网、央视频等多家媒体记者的关注,并获得广泛关注与报道。 鹰瞳科技(Airdoc)AI健康产品在服贸会大放异彩,备受关注。在2号馆公益展区优促计划主题展上,鹰瞳Airdoc邀请参会嘉宾亲测PBM视力康复仪等创新产品,赢得参会嘉宾的广泛青睐,而同期PBM视力康复仪在学界也展现优势。 PBM 技术与脑机接口关联及在近视问题上的探索:「政策推动与技术融合」 近年来,随着科学技术的迅猛发展,脑机接口(Brain-Computer Interface, BCI)技术已成为前沿科技创新的重要方向。与此同时,光生物调节(PBM)作为一种新兴技术路径,也逐渐崭露头角,并与脑机接口技术形成多层面的交叉与融合。 脑机接口通过在脑与机器之间建立信息通道,实现生物智能与机器智能的协同交互,是生命科学和信息科学融合发展的前","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1757840188560,"gmtModify":1757855674863,"symbols":["02251","161631","PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/7caf30f1aad91fb2430854f79635785d","width":"1920","height":"1080"},{"url":"https://static.tigerbbs.com/60c96e0a3e96b4b643eb0c2310136efa","width":"720","height":"479"},{"url":"https://static.tigerbbs.com/1f81762564f3309f4d406faa615dbf78","width":"1920","height":"1080"}],"repostCount":0,"viewCount":32558,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/478447991959848","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":4535,"displayRows":2,"foldSize":0,"authorId":"4096767797929640"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.331414135816272","cardData":[{"tweetId":"331414135816272","author":{"authorId":"3483669283508638","idStr":"3483669283508638","name":"我就是阿硕","avatar":"https://static.tigerbbs.com/ef3a6f12848da8815606073e69dae4be","userType":1,"introduction":"","crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":10732,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/PBM\">$Psyence Biomedical Ltd(PBM)$ </a> ","plainDigest":"$Psyence Biomedical Ltd(PBM)$","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1721918395541,"gmtModify":1721918399130,"symbols":["PBM"],"themeIds":["5bfad02ab61749c8bfe6573ac7bbe8a3"],"themes":[{"themeId":"5bfad02ab61749c8bfe6573ac7bbe8a3","themeType":0,"name":"晒晒更赚钱"}],"popularizeThemeFlag":false,"imageCount":1,"images":[{"url":"https://static.tigerbbs.com/f075bd49b99a48c1fa3f94d7556a9a68","width":"898","height":"1530"}],"repostCount":0,"viewCount":1991,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/331414135816272","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":["晒单贴"],"commentAndTweetFlag":false,"upFlag":false,"length":27,"displayRows":2,"foldSize":0,"authorId":"3483669283508638"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.319226877493304","cardData":[{"tweetId":"319226877493304","author":{"authorId":"4138621111675080","idStr":"4138621111675080","name":"小谷AI洞察","avatar":"https://static.tigerbbs.com/ed34002d87b2f93e10d511702e995ab8","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/PBM\">$Psyence Biomedical Ltd(PBM)$ </a> 套人的东西,早上进来了,现在迭得只剩下1/3了","plainDigest":"$Psyence Biomedical Ltd(PBM)$ 套人的东西,早上进来了,现在迭得只剩下1/3了","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1718961838876,"gmtModify":1718961840577,"symbols":["PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1750,"likeCount":0,"liked":false,"collected":false,"commentCount":2,"hotComments":[{"id":"319220491129096","author":{"authorId":"3505357785858052","idStr":"3505357785858052","name":"愫暮_9408","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"fanSize":1,"starInvestorFlag":false},"content":"你是因为啥原因买这个股啊[捂脸]","plainContent":"你是因为啥原因买这个股啊[捂脸]","likeCount":0,"commentType":"hot","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/319226877493304","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":68,"displayRows":2,"foldSize":0,"authorId":"4138621111675080"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.319126052671736","cardData":[{"tweetId":"319126052671736","author":{"authorId":"4138621111675080","idStr":"4138621111675080","name":"小谷AI洞察","avatar":"https://static.tigerbbs.com/ed34002d87b2f93e10d511702e995ab8","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/PBM\">$Psyence Biomedical Ltd(PBM)$ </a> 1块进的,腰斩了","plainDigest":"$Psyence Biomedical Ltd(PBM)$ 1块进的,腰斩了","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1718926841536,"gmtModify":1718926842935,"symbols":["PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1247,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/319126052671736","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":41,"displayRows":2,"foldSize":0,"authorId":"4138621111675080"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.319083968229592","cardData":[{"tweetId":"319083968229592","author":{"authorId":"4138621111675080","idStr":"4138621111675080","name":"小谷AI洞察","avatar":"https://static.tigerbbs.com/ed34002d87b2f93e10d511702e995ab8","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"wearingBadge":{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","individualDisplayEnabled":0,"individualDisplaySort":0},"individualDisplayBadges":[],"fanSize":26,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/PBM\">$Psyence Biomedical Ltd(PBM)$ </a> ?","plainDigest":"$Psyence Biomedical Ltd(PBM)$ ?","sourceLanguage":"EN","currentLanguage":"EN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1718916560376,"gmtModify":1718916561789,"symbols":["PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":560,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/319083968229592","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":28,"displayRows":2,"foldSize":0,"authorId":"4138621111675080"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.296104372494592","cardData":[{"tweetId":"296104372494592","author":{"authorId":"3505357785858052","idStr":"3505357785858052","name":"愫暮_9408","avatar":"https://static.laohu8.com/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"digest":"<a href=\"https://laohu8.com/S/PBM\">$Psyence Biomedical Ltd(PBM)$</a> 怎么能一直跌[捂脸] [捂脸] ","plainDigest":"$Psyence Biomedical Ltd(PBM)$ 怎么能一直跌[捂脸] [捂脸]","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1713321089094,"gmtModify":1713321168136,"symbols":["PBM"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":1862,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/296104372494592","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":51,"displayRows":2,"foldSize":0,"authorId":"3505357785858052"}],"position":0}],"size":9,"extra":{"requestId":"6d4d74f17d2044c6914a456c640c2a42","feedVerCode":"2"}},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"20264622","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025098716-PBM","pdf_url":"","pub_time":1760414400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"PBM","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[修订]招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/0001213900-25-098716-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"AMENDMENT NO. 2 TO FORM F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ea0261076-f1a2_psyence.htm","primary":true,"translateUrl":"","linkName":"ea0261076-f1a2_psyence.htm","type":"F-1/A","id":"NTFILESVr7zTVTbUCNvSYt","market":"us","size":1978704},{"description":"CONSENT OF MNP LLP","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ea026107601ex5-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea026107601ex5-1_psyence.htm","type":"EX-5.1","id":"NTFILEGkHSLJuVVmsEZrpi","market":"us","size":20580},{"description":"CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ea026107601ex23-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea026107601ex23-1_psyence.htm","type":"EX-23.1","id":"NTFILEDj92G12fAGyvyvAU","market":"us","size":2404},{"description":"GRAPHIC","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_001.jpg","primary":false,"translateUrl":"","linkName":"image_001.jpg","type":"GRAPHIC","id":"NTFILEEwRC2iF2PMLrUcNj","market":"us","size":62003},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_002.jpg","primary":false,"translateUrl":"","linkName":"image_002.jpg","type":"GRAPHIC","id":"NTFILE7TJvB8sDsFyngxFg","market":"us","size":44426},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_003.jpg","primary":false,"translateUrl":"","linkName":"image_003.jpg","type":"GRAPHIC","id":"NTFILE68UVBe2nFZJLZwiV","market":"us","size":78440},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_004.jpg","primary":false,"translateUrl":"","linkName":"image_004.jpg","type":"GRAPHIC","id":"NTFILE7XsMKrNDaY8vya5H","market":"us","size":79345},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_005.jpg","primary":false,"translateUrl":"","linkName":"image_005.jpg","type":"GRAPHIC","id":"NTFILE82tEbbYZDY3hpJRR","market":"us","size":66165},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_006.jpg","primary":false,"translateUrl":"","linkName":"image_006.jpg","type":"GRAPHIC","id":"NTFILEAE17ae9pT9nqrEZb","market":"us","size":53229},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/image_007.jpg","primary":false,"translateUrl":"","linkName":"image_007.jpg","type":"GRAPHIC","id":"NTFILEoE3Y2eJsY968d6z9","market":"us","size":91722},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/fin_001.jpg","primary":false,"translateUrl":"","linkName":"fin_001.jpg","type":"GRAPHIC","id":"NTFILECSwCg8e1xZXsyLE5","market":"us","size":37346},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/fin_002.jpg","primary":false,"translateUrl":"","linkName":"fin_002.jpg","type":"GRAPHIC","id":"NTFILE7xTePTPJnzgpWfjC","market":"us","size":7153},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/fin_003.jpg","primary":false,"translateUrl":"","linkName":"fin_003.jpg","type":"GRAPHIC","id":"NTFILE6vvVUdxzamcuoFXR","market":"us","size":4220},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ex5-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex5-1_001.jpg","type":"GRAPHIC","id":"NTFILE8q9fSiGgb1HS1kVh","market":"us","size":3286},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ex23-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_001.jpg","type":"GRAPHIC","id":"NTFILE5JerMYjYYDvXbN5N","market":"us","size":8147},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ex23-1_003.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_003.jpg","type":"GRAPHIC","id":"NTFILE4KMvKys7qzStFCJx","market":"us","size":2878},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025098716/ex23-1_002.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_002.jpg","type":"GRAPHIC","id":"NTFILE94HYdfLiNkpRZJUY","market":"us","size":13117}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[修订]招股说明书","pubTime":"2025-10-14 12:00","pubTimestamp":1760414400,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20242581","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025096665-PBM","pdf_url":"","pub_time":1759723200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","symbol":"PBM","title":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","titleType":"[修订]招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/0001213900-25-096665-index.htm","us_notice_code":"Form F-1/A","us_title_en":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"AMENDMENT NO. 1 TO FORM F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ea0254854-f1a1_psyence.htm","primary":true,"translateUrl":"","linkName":"ea0254854-f1a1_psyence.htm","type":"F-1/A","id":"NTFILEB92CV1E1bsRvv8Hz","market":"us","size":1975743},{"description":"OPINION OF WEIRFOULDS LLP","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ea025485401ex5-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025485401ex5-1_psyence.htm","type":"EX-5.1","id":"NTFILEDRxaAQokg2WDbMjP","market":"us","size":20518},{"description":"CONSENT OF MNP LLP (PCAOB ID: 1930)","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ea025485401ex23-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025485401ex23-1_psyence.htm","type":"EX-23.1","id":"NTFILE4aJ7Y8odMCYJ3Yn7","market":"us","size":3919},{"description":"FILING FEE TABLE","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ea025485401ex-fee_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025485401ex-fee_psyence.htm","type":"EX-FILING FEES","id":"NTFILECt2vHRpgtzB43ULN","market":"us","size":23925},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_001.jpg","primary":false,"translateUrl":"","linkName":"image_001.jpg","type":"GRAPHIC","id":"NTFILEn7d4LjP373T42pMZ","market":"us","size":62003},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_002.jpg","primary":false,"translateUrl":"","linkName":"image_002.jpg","type":"GRAPHIC","id":"NTFILE4ayQuiUu9Ez379vb","market":"us","size":44426},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_003.jpg","primary":false,"translateUrl":"","linkName":"image_003.jpg","type":"GRAPHIC","id":"NTFILEEuCJuXWWqbFffw4g","market":"us","size":78440},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_004.jpg","primary":false,"translateUrl":"","linkName":"image_004.jpg","type":"GRAPHIC","id":"NTFILEHX6kK4SRFe1sGaqV","market":"us","size":79345},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_005.jpg","primary":false,"translateUrl":"","linkName":"image_005.jpg","type":"GRAPHIC","id":"NTFILEDGdcSyqeiwtCws45","market":"us","size":66165},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_006.jpg","primary":false,"translateUrl":"","linkName":"image_006.jpg","type":"GRAPHIC","id":"NTFILEHGFpy4zeLfMxi1Yi","market":"us","size":53229},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/image_007.jpg","primary":false,"translateUrl":"","linkName":"image_007.jpg","type":"GRAPHIC","id":"NTFILE7tZqafrPjQsaLFkJ","market":"us","size":91722},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/fin_001.jpg","primary":false,"translateUrl":"","linkName":"fin_001.jpg","type":"GRAPHIC","id":"NTFILE4uCSBUp6qpVS4qm2","market":"us","size":37346},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/fin_002.jpg","primary":false,"translateUrl":"","linkName":"fin_002.jpg","type":"GRAPHIC","id":"NTFILE8qf2qi72g9jBaryf","market":"us","size":7153},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/fin_003.jpg","primary":false,"translateUrl":"","linkName":"fin_003.jpg","type":"GRAPHIC","id":"NTFILE9NQX8kKEYFxAYzA6","market":"us","size":4220},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ex5-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex5-1_001.jpg","type":"GRAPHIC","id":"NTFILErsZdTcud2GWSMbcb","market":"us","size":3286},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ex23-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_001.jpg","type":"GRAPHIC","id":"NTFILE8CmU4EBQjojPQUn4","market":"us","size":8147},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ex23-1_002.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_002.jpg","type":"GRAPHIC","id":"NTFILE3CrXsQ7VfQ7oHwCs","market":"us","size":13117},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025096665/ex23-1_003.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_003.jpg","type":"GRAPHIC","id":"NTFILEBqFzo7xGQ1b34Qrh","market":"us","size":2878}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"[Amend]Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"[修订]招股说明书","pubTime":"2025-10-06 12:00","pubTimestamp":1759723200,"title_zh":"Form F-1/A - Registration statement for certain foreign private issuers: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19913398","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025067748-PBM","pdf_url":"","pub_time":1753416000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]","symbol":"PBM","title":"Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]","titleType":"[修订]年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067748/0001213900-25-067748-index.htm","us_notice_code":"Form 20-F/A","us_title_en":"Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"AMENDMENT NO. 1 TO FORM 20-F","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067748/ea0250204-20fa1_psyence.htm","primary":true,"translateUrl":"","linkName":"ea0250204-20fa1_psyence.htm","type":"20-F/A","id":"NTFILEGThTHbT9Lohd1z1n","market":"us","size":47883},{"description":"CERTIFICATION","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067748/ea025020401ex12-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025020401ex12-1_psyence.htm","type":"EX-12.1","id":"NTFILE7RZNmFhqttjNvqQ7","market":"us","size":11976},{"description":"CERTIFICATION","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067748/ea025020401ex12-2_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025020401ex12-2_psyence.htm","type":"EX-12.2","id":"NTFILEHfv1sMg13Fqia21J","market":"us","size":12002}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"[Rev.]Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"[修订]年度报告","pubTime":"2025-07-25 12:00","pubTimestamp":1753416000,"title_zh":"Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19905517","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025067048-PBM","pdf_url":"","pub_time":1753243200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"PBM","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/0001213900-25-067048-index.htm","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"REGISTRATION STATEMENT","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ea0250018-s8_psyence.htm","primary":true,"translateUrl":"","linkName":"ea0250018-s8_psyence.htm","type":"S-8","id":"NTFILE2Pd3WHQUDLMzMjhb","market":"us","size":48231},{"description":"OPINION OF WEIRFOULDS LLP","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ea025001801ex5-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025001801ex5-1_psyence.htm","type":"EX-5.1","id":"NTFILE2XhHtRWas7Z8zsr1","market":"us","size":22238},{"description":"CONSENT OF MNP LLP","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ea025001801ex23-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025001801ex23-1_psyence.htm","type":"EX-23.1","id":"NTFILEDdNcjguTGZiRQC8T","market":"us","size":4634},{"description":"FILING FEE TABLE","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ea025001801ex-fee_psyence.htm","primary":false,"translateUrl":"","linkName":"ea025001801ex-fee_psyence.htm","type":"EX-FILING FEES","id":"NTFILE63Lke5Tb9c6uU4Bd","market":"us","size":11514},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ex5-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex5-1_001.jpg","type":"GRAPHIC","id":"NTFILEDu2hHToKWnKY3w29","market":"us","size":10171},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ex23-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_001.jpg","type":"GRAPHIC","id":"NTFILE6cHEiYKw4PVNPiRv","market":"us","size":26263},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025067048/ex23-1_002.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_002.jpg","type":"GRAPHIC","id":"NTFILE8dJAHZJZekxUqoZq","market":"us","size":7512}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2025-07-23 12:00","pubTimestamp":1753243200,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19808853","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025057893-PBM","pdf_url":"","pub_time":1750824000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","symbol":"PBM","title":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","titleType":"年度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/0001213900-25-057893-index.htm","us_notice_code":"Form 20-F","us_title_en":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"ANNUAL REPORT","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea0246623-20f_psyence.htm","primary":true,"translateUrl":"","linkName":"ea0246623-20f_psyence.htm","type":"20-F","id":"NTFILECvNRD2ocoTif39Gw","market":"us","size":1887094},{"description":"CERTIFICATION","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea024662301ex12-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea024662301ex12-1_psyence.htm","type":"EX-12.1","id":"NTFILEBtxyknKgvrfsLfS3","market":"us","size":11931},{"description":"CERTIFICATION","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea024662301ex12-2_psyence.htm","primary":false,"translateUrl":"","linkName":"ea024662301ex12-2_psyence.htm","type":"EX-12.2","id":"NTFILE4PS2gxBmfQpijEgJ","market":"us","size":11957},{"description":"CERTIFICATION","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea024662301ex13-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea024662301ex13-1_psyence.htm","type":"EX-13.1","id":"NTFILEvyeLeSQKjFHWSGoE","market":"us","size":5231},{"description":"CONSENT OF MNP LLP","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea024662301ex23-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea024662301ex23-1_psyence.htm","type":"EX-23.1","id":"NTFILE4fQmSFQHo2ixxy7v","market":"us","size":3333},{"description":"COMPENSATION CLAWBACK POLICY","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ea024662301ex97-1_psyence.htm","primary":false,"translateUrl":"","linkName":"ea024662301ex97-1_psyence.htm","type":"EX-97.1","id":"NTFILECQ6avszxULuh4rt4","market":"us","size":17358},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_001.jpg","primary":false,"translateUrl":"","linkName":"image_001.jpg","type":"GRAPHIC","id":"NTFILEC236qkmcHJqhrzc1","market":"us","size":63420},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_002.jpg","primary":false,"translateUrl":"","linkName":"image_002.jpg","type":"GRAPHIC","id":"NTFILE8ywDADB2Z2k6AS68","market":"us","size":44242},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_003.jpg","primary":false,"translateUrl":"","linkName":"image_003.jpg","type":"GRAPHIC","id":"NTFILEJ81GK3FkKmwk8yNC","market":"us","size":78328},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_004.jpg","primary":false,"translateUrl":"","linkName":"image_004.jpg","type":"GRAPHIC","id":"NTFILEH415ZMLcoQiMhisA","market":"us","size":79245},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_005.jpg","primary":false,"translateUrl":"","linkName":"image_005.jpg","type":"GRAPHIC","id":"NTFILE5AkwKtiUEFn1M12X","market":"us","size":66007},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_006.jpg","primary":false,"translateUrl":"","linkName":"image_006.jpg","type":"GRAPHIC","id":"NTFILE3Ea1TvgvanZ6vmP4","market":"us","size":50673},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_007.jpg","primary":false,"translateUrl":"","linkName":"image_007.jpg","type":"GRAPHIC","id":"NTFILEBQyy6ggsx6oGUXMA","market":"us","size":91492},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/image_008.jpg","primary":false,"translateUrl":"","linkName":"image_008.jpg","type":"GRAPHIC","id":"NTFILEF6Jit7yYAtVCbejW","market":"us","size":37346},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/fin_001.jpg","primary":false,"translateUrl":"","linkName":"fin_001.jpg","type":"GRAPHIC","id":"NTFILEEKqQzKZceYGvguEL","market":"us","size":7153},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/fin_002.jpg","primary":false,"translateUrl":"","linkName":"fin_002.jpg","type":"GRAPHIC","id":"NTFILEBNVTxJYJ1BDpnbwA","market":"us","size":4220},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ex23-1_001.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_001.jpg","type":"GRAPHIC","id":"NTFILEHdsgs8fJU4p3g9da","market":"us","size":7153},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025057893/ex23-1_002.jpg","primary":false,"translateUrl":"","linkName":"ex23-1_002.jpg","type":"GRAPHIC","id":"NTFILECHRZiMeuHwRv5fM1","market":"us","size":4973}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"年度报告","pubTime":"2025-06-25 12:00","pubTimestamp":1750824000,"title_zh":"Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19382050","market":"us","labels":[],"media":"sec.gov","original_id":"AN121390025023419-PBM","pdf_url":"","pub_time":1741838400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"PBM","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025023419/0001213900-25-023419-index.htm","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000121390025023419/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILECtYbTdQojiJ2dsRP","market":"us","size":5846}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2025-03-13 12:00","pubTimestamp":1741838400,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19185067","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465925006681-PBM","pdf_url":"","pub_time":1738040400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"PBM","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000110465925006681/0001104659-25-006681-index.htm","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000110465925006681/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILEB1QxS1sK2LDgmSfJ","market":"us","size":5038}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2025-01-28 13:00","pubTimestamp":1738040400,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19074205","market":"us","labels":[],"media":"sec.gov","original_id":"AN141057825000041-PBM","pdf_url":"","pub_time":1737694800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1 - Registration statement for certain foreign private issuers","symbol":"PBM","title":"Form F-1 - Registration statement for certain foreign private issuers","titleType":"招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/0001410578-25-000041-index.htm","us_notice_code":"Form F-1","us_title_en":"Form F-1 - Registration statement for certain foreign private issuers","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1.htm","primary":true,"translateUrl":"","linkName":"pbm-20240930xf1.htm","type":"F-1","id":"NTFILE5SuU4MyuLZhGgBrj","market":"us","size":3883528},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex5d1.htm","primary":false,"translateUrl":"","linkName":"pbm-20240930xex5d1.htm","type":"EX-5.1","id":"NTFILEHLc4L4JgtipGZag4","market":"us","size":24443},{"description":"EX-10.37","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex10d37.htm","primary":false,"translateUrl":"","linkName":"pbm-20240930xex10d37.htm","type":"EX-10.37","id":"NTFILE9ZNNv5DJXDEKY9MA","market":"us","size":73889},{"description":"EX-10.38","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex10d38.htm","primary":false,"translateUrl":"","linkName":"pbm-20240930xex10d38.htm","type":"EX-10.38","id":"NTFILEF3mZJKu6254J7s18","market":"us","size":21844},{"description":"EX-23.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex23d1.htm","primary":false,"translateUrl":"","linkName":"pbm-20240930xex23d1.htm","type":"EX-23.1","id":"NTFILEFzpwTjFU4Sf4Qzgf","market":"us","size":5756},{"description":"EX-FILING FEES","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xexfees.htm","primary":false,"translateUrl":"","linkName":"pbm-20240930xexfees.htm","type":"EX-FILING FEES","id":"NTFILEAE4B1tsjCK2HdmsQ","market":"us","size":58856},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1008.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1008.jpg","type":"GRAPHIC","id":"NTFILEDVXRRagLJLSQrFFH","market":"us","size":62121},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1010.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1010.jpg","type":"GRAPHIC","id":"NTFILEFzDm7nwZvropgf5h","market":"us","size":34396},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1016.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1016.jpg","type":"GRAPHIC","id":"NTFILE8pd94ciCSxBrMSWh","market":"us","size":44365},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1017.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1017.jpg","type":"GRAPHIC","id":"NTFILE9MJT4ySYz1yFJYF2","market":"us","size":40535},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1018.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1018.jpg","type":"GRAPHIC","id":"NTFILE9ck5dWbLGxLM2n4u","market":"us","size":34284},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1019.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1019.jpg","type":"GRAPHIC","id":"NTFILEkFVZpRB1xUKXfpo2","market":"us","size":26965},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1020.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1020.jpg","type":"GRAPHIC","id":"NTFILE74PxmPVgezGedW3W","market":"us","size":50791},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1023.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1023.jpg","type":"GRAPHIC","id":"NTFILEFhHAiLa7qx7NoXLV","market":"us","size":20956},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1024.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1024.jpg","type":"GRAPHIC","id":"NTFILEFcFXvB8kQACwBb51","market":"us","size":2446},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1025.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1025.jpg","type":"GRAPHIC","id":"NTFILEEnozFTTvWM4w88Ct","market":"us","size":16558},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xf1026.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xf1026.jpg","type":"GRAPHIC","id":"NTFILE4NqxLccK5mJje4hV","market":"us","size":5913},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex10d37001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex10d37001.jpg","type":"GRAPHIC","id":"NTFILE2K7V8CpXPEAfQemf","market":"us","size":10278},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex10d38001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex10d38001.jpg","type":"GRAPHIC","id":"NTFILEASMu3zQRMzPdWBVg","market":"us","size":16528},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex23d1001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex23d1001.jpg","type":"GRAPHIC","id":"NTFILEAnzBPvdLZHaUUfNf","market":"us","size":2225},{"description":"GRAPHIC","seq":21,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex23d1002.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex23d1002.jpg","type":"GRAPHIC","id":"NTFILEAtxrHyNceRRUkeft","market":"us","size":2446},{"description":"GRAPHIC","seq":22,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex23d1003.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex23d1003.jpg","type":"GRAPHIC","id":"NTFILEJ2KGLfNJN8Fc4PMe","market":"us","size":2244},{"description":"GRAPHIC","seq":23,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057825000041/pbm-20240930xex5d1001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240930xex5d1001.jpg","type":"GRAPHIC","id":"NTFILEGHJUfsHJZRRzEQ7g","market":"us","size":7345}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"招股说明书","pubTime":"2025-01-24 13:00","pubTimestamp":1737694800,"title_zh":"Form F-1 - Registration statement for certain foreign private issuers","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"19091067","market":"us","labels":[],"media":"sec.gov","original_id":"AN110465924132289-PBM","pdf_url":"","pub_time":1735534800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form CORRESP - Correspondence","symbol":"PBM","title":"Form CORRESP - Correspondence","titleType":"SEC问询函","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000110465924132289/0001104659-24-132289-index.htm","us_notice_code":"Form CORRESP","us_title_en":"Form CORRESP - Correspondence","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000110465924132289/filename1.htm","primary":true,"translateUrl":"","linkName":"filename1.htm","type":"CORRESP","id":"NTFILE9WzQdA2SkYcxq7bP","market":"us","size":5584}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Correspondence","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"SEC问询函","pubTime":"2024-12-30 13:00","pubTimestamp":1735534800,"title_zh":"Form CORRESP - Correspondence","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18968702","market":"us","labels":[],"media":"sec.gov","original_id":"AN141057824002107-PBM","pdf_url":"","pub_time":1734670800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form F-1 - Registration statement for certain foreign private issuers","symbol":"PBM","title":"Form F-1 - Registration statement for certain foreign private issuers","titleType":"招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/0001410578-24-002107-index.htm","us_notice_code":"Form F-1","us_title_en":"Form F-1 - Registration statement for certain foreign private issuers","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"F-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1.htm","primary":true,"translateUrl":"","linkName":"pbm-20240331xf1.htm","type":"F-1","id":"NTFILE4nFpgRrjVeDGTjz6","market":"us","size":2866619},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex5d1.htm","primary":false,"translateUrl":"","linkName":"pbm-20240331xex5d1.htm","type":"EX-5.1","id":"NTFILE6XnNRXtVkbP58exn","market":"us","size":35728},{"description":"EX-23.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex23d1.htm","primary":false,"translateUrl":"","linkName":"pbm-20240331xex23d1.htm","type":"EX-23.1","id":"NTFILEDxb5d875qBgf8HQd","market":"us","size":5738},{"description":"EX-FILING FEES","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xexfees.htm","primary":false,"translateUrl":"","linkName":"pbm-20240331xexfees.htm","type":"EX-FILING FEES","id":"NTFILE4kzTjMuoQMqAqLxG","market":"us","size":45085},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1008.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1008.jpg","type":"GRAPHIC","id":"NTFILEC5DjS7qKbpkbJCLh","market":"us","size":62121},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1010.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1010.jpg","type":"GRAPHIC","id":"NTFILEHJdQR9YiQcDa2Sgs","market":"us","size":34396},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1016.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1016.jpg","type":"GRAPHIC","id":"NTFILE28zX2FxEv78x4iCM","market":"us","size":44365},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1017.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1017.jpg","type":"GRAPHIC","id":"NTFILEGT1XpwYxBQ4p6sPC","market":"us","size":40535},{"description":"GRAPHIC","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1018.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1018.jpg","type":"GRAPHIC","id":"NTFILEBXAqkNPk8323CxhT","market":"us","size":34284},{"description":"GRAPHIC","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1019.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1019.jpg","type":"GRAPHIC","id":"NTFILE2oHozcysfDDXLPpP","market":"us","size":26965},{"description":"GRAPHIC","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1020.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1020.jpg","type":"GRAPHIC","id":"NTFILE8GCDZB3fDRyx38Yf","market":"us","size":50791},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1023.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1023.jpg","type":"GRAPHIC","id":"NTFILE6z6BypUe2kxxJb3D","market":"us","size":20956},{"description":"GRAPHIC","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1024.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1024.jpg","type":"GRAPHIC","id":"NTFILE6A8n3GPL9HVDp3Aa","market":"us","size":6441},{"description":"GRAPHIC","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1025.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1025.jpg","type":"GRAPHIC","id":"NTFILEAfkpKDkeULdsNNMx","market":"us","size":2446},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1026.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1026.jpg","type":"GRAPHIC","id":"NTFILE8WjQuQ5hMC9FqG96","market":"us","size":2244},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xf1027.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xf1027.jpg","type":"GRAPHIC","id":"NTFILE6GqbCHTJSBauYCXt","market":"us","size":2170},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex23d1001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xex23d1001.jpg","type":"GRAPHIC","id":"NTFILEA3BvccVXvv2p7ESD","market":"us","size":2225},{"description":"GRAPHIC","seq":18,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex23d1002.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xex23d1002.jpg","type":"GRAPHIC","id":"NTFILEBPJ8Lzrv15ScDYrY","market":"us","size":2446},{"description":"GRAPHIC","seq":19,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex23d1003.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xex23d1003.jpg","type":"GRAPHIC","id":"NTFILE3ostxkLc9njaSTdG","market":"us","size":2244},{"description":"GRAPHIC","seq":20,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1985062/000141057824002107/pbm-20240331xex5d1001.jpg","primary":false,"translateUrl":"","linkName":"pbm-20240331xex5d1001.jpg","type":"GRAPHIC","id":"NTFILEAPcy74kz34fy5JTW","market":"us","size":7345}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"招股说明书","pubTime":"2024-12-20 13:00","pubTimestamp":1734670800,"title_zh":"Form F-1 - Registration statement for certain foreign private issuers","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18943023","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312524277985-PBM","pdf_url":"","pub_time":1734066000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"PBM","title":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000119312524277985/0001193125-24-277985-index.htm","us_notice_code":"Form SC 13G","us_title_en":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"SC 13G","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1952614/000119312524277985/d910600dsc13g.htm","primary":true,"translateUrl":"","linkName":"d910600dsc13g.htm","type":"SC 13G","id":"NTFILE5BG2UiWEQDuazAjR","market":"us","size":32806}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2024-12-13 13:00","pubTimestamp":1734066000,"title_zh":"Form SC 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18922167","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312524273261-PBM","pdf_url":"","pub_time":1733720400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","symbol":"PBM","title":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000119312524273261/0001193125-24-273261-index.htm","us_notice_code":"Form SC 13G/A","us_title_en":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"SC 13G/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524273261/d931062dsc13ga.htm","primary":true,"translateUrl":"","linkName":"d931062dsc13ga.htm","type":"SC 13G/A","id":"NTFILEAyDkGg3GN2F3yJ8i","market":"us","size":109026},{"description":"EX-99.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524273261/d931062dex991.htm","primary":false,"translateUrl":"","linkName":"d931062dex991.htm","type":"EX-99.1","id":"NTFILEDLyQFdfzARS1WSnu","market":"us","size":6226}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2024-12-09 13:00","pubTimestamp":1733720400,"title_zh":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18907428","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312524270735-PBM","pdf_url":"","pub_time":1733288400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","symbol":"PBM","title":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000119312524270735/0001193125-24-270735-index.htm","us_notice_code":"Form SC 13G/A","us_title_en":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"SC 13G/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524270735/d900537dsc13ga.htm","primary":true,"translateUrl":"","linkName":"d900537dsc13ga.htm","type":"SC 13G/A","id":"NTFILE4px9RUFTfkJh1tfU","market":"us","size":107384},{"description":"EX-99.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524270735/d900537dex991.htm","primary":false,"translateUrl":"","linkName":"d900537dex991.htm","type":"EX-99.1","id":"NTFILEC6Xfo7HxdcPySRXM","market":"us","size":6489}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2024-12-04 13:00","pubTimestamp":1733288400,"title_zh":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18827313","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312524256694-PBM","pdf_url":"","pub_time":1731474000000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","symbol":"PBM","title":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000119312524256694/0001193125-24-256694-index.htm","us_notice_code":"Form SC 13G/A","us_title_en":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"SC 13G/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524256694/d872099dsc13ga.htm","primary":true,"translateUrl":"","linkName":"d872099dsc13ga.htm","type":"SC 13G/A","id":"NTFILEABaw6NQZJV1CGc7H","market":"us","size":107846},{"description":"EX-99.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524256694/d872099dex991.htm","primary":false,"translateUrl":"","linkName":"d872099dex991.htm","type":"EX-99.1","id":"NTFILE7f3pWnWA86v7rRzJ","market":"us","size":6451}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2024-11-13 13:00","pubTimestamp":1731474000,"title_zh":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"18821047","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312524255701-PBM","pdf_url":"","pub_time":1731387600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","symbol":"PBM","title":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/1985062/000119312524255701/0001193125-24-255701-index.htm","us_notice_code":"Form SC 13G/A","us_title_en":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"SC 13G/A","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524255701/d872099dsc13ga.htm","primary":true,"translateUrl":"","linkName":"d872099dsc13ga.htm","type":"SC 13G/A","id":"NTFILEEeK9R9ZS3AZhnbUv","market":"us","size":107912},{"description":"EX-99.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1910592/000119312524255701/d872099dex991.htm","primary":false,"translateUrl":"","linkName":"d872099dex991.htm","type":"EX-99.1","id":"NTFILE3CJVKz776v5u1B6c","market":"us","size":6451}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2024-11-12 13:00","pubTimestamp":1731387600,"title_zh":"Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":-0.3922},{"period":"1month","weight":-0.3758},{"period":"3month","weight":-0.719},{"period":"6month","weight":-0.818},{"period":"1year","weight":-0.951},{"period":"ytd","weight":-0.9447}],"compareEarnings":[{"period":"1week","weight":0.0134},{"period":"1month","weight":0.0439},{"period":"3month","weight":0.0406},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1738}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Psyence Biomedical Ltd是一家生命科学生物技术公司,率先在心理健康和福祉中使用天然迷幻药物。它开发天然的迷幻药产品,用于在姑息治疗背景下治愈心理创伤及其心理健康后果。该公司已开始临床试验程序,以评估其候选产品的安全性和有效性。它在其位于南部非洲的联邦许可的 ISO22000 设施中种植天然迷幻药蘑菇。该产品是为出口到世界各地的合作伙伴而生产的,然后加工成标准化的封装产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.259967},{"month":2,"riseRate":0.5,"avgChangeRate":-0.224323},{"month":3,"riseRate":0.75,"avgChangeRate":0.142672},{"month":4,"riseRate":0.5,"avgChangeRate":-0.110089},{"month":5,"riseRate":0.5,"avgChangeRate":0.047066},{"month":6,"riseRate":0.75,"avgChangeRate":-0.123687},{"month":7,"riseRate":0.75,"avgChangeRate":0.230876},{"month":8,"riseRate":0.5,"avgChangeRate":-0.181154},{"month":9,"riseRate":0.75,"avgChangeRate":-0.153581},{"month":10,"riseRate":0.25,"avgChangeRate":-0.079288},{"month":11,"riseRate":0.25,"avgChangeRate":-0.211015},{"month":12,"riseRate":0.25,"avgChangeRate":-0.239218}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"aProfile":null}}}